Turicibacter sanguinis is a candidate gut microbial pathobiont that promotes metabolic dysfunction-associated steatohepatitis
mSystems · 2026
DOI: 10.1128/msystems.00292-26 ↗Kurz gefasst
Fachartikel in der Zeitschrift mSystems, 2026. Verfasst von Jing Guo und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacology, National Clinical Research Center for Geriatric Disease, Xiangya Hospital, Central South University, Changsha, H…. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Fatty Liver. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Fundamental Research Funds for Central Universities of the Central South University, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Emerging evidence points to the gut microbiota’s involvement in metabolic dysfunction-associated steatohepatitis (MASH), yet the specific causative microbes remain largely unidentified. This study aimed to identify and functionally characterize candidate microbial pathobionts to MASH progression. Differentially abundant microbes were identified by 16S rRNA sequencing in a choline-deficient, L-amino acid-defined, high-fat diet MASH model, validated in other animal MASH models and in public clinical metagenomic data sets, then screened for consistently altered gut taxa. A candidate underwent functional validation via directed oral administration in mice. Mechanisms were explored through bile acid profiling by UHPLC-MS/MS and FXR signaling analysis by qPCR and immunohistochemistry. Additionally, fecal samples from MASH patients before and after treatment were analyzed to correlate microbial abundance with treatment response. Turicibacter sanguinis was consistently enriched in all MASH models and public data sets, with abundance correlating positively with liver injury markers. Its increased abundance exacerbated steatosis, inflammation, and fibrosis in healthy and diseased mice. Mechanistically, Turicibacter sanguinis altered bile acid composition, thereby increasing conjugated and decreasing unconjugated species, and inhibited hepatic FXR signaling, accompanied by suppressed SHP and elevated CYP7A1 and SREBP1c expression, which is consistent with enhanced bile acid synthesis and lipid accumulation. Futhermore, after pharmacotherapy, reduced Turicibater sanguinis levels correlated positively with alanine aminotransferase (ALT) and aspartate aminotransferase (AST) improvements. In conclusion, Turicibacter sanguinis is a clinically relevant microbial pathogen that exacerbated MASH by inducing bile acid dysregulation and suppressing FXR signaling, highlighting its potential as a candidate biomarker for disease monitoring and motivating future evaluation of targeted microbiome interventions. IMPORTANCE Metabolic dysfunction-associated steatohepatitis (MASH) is a growing global health problem with limited treatment options. Although the gut microbiome has been implicated in MASH, the specific bacterial strains that directly drive disease progression remain largely unknown. This study identified Turicibacter sanguinis as a candidate gut microbial pathobiont that promotes MASH, demonstrating its significant enrichment in both animal models and patient samples. By disrupting hepatic metabolic signaling, this bacterium promotes bile acid synthesis and exacerbates liver fat accumulation, inflammation, and fibrosis. Following effective treatment, its abundance decreased significantly in patients. These findings indicate that Turicibacter sanguinis holds promise as a potential target for developing novel microbiome-based diagnostic and therapeutic approaches for MASH.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Pharmacology, National Clinical Research Center for Geriatric Disease, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Organ Transplantation, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Department of Hepatobiliary Surgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Förderung
- National Natural Science Foundation of China
- Fundamental Research Funds for Central Universities of the Central South University
- Natural Science Foundation of Hunan Province
Zitieren
APA
Guo, J., Xiang, Z., Hu, F., Zhang, S., Han, W., Ding, X., Wang, X., Ye, M., Chen, J., Rao, T., Wu, L., Lian, G., Zhang, W., Huang, Y., & Chen, Y. (2026). Turicibacter sanguinis is a candidate gut microbial pathobiont that promotes metabolic dysfunction-associated steatohepatitis. mSystems. https://doi.org/10.1128/msystems.00292-26
Vancouver
Guo J, Xiang Z, Hu F, Zhang S, Han W, Ding X, et al. Turicibacter sanguinis is a candidate gut microbial pathobiont that promotes metabolic dysfunction-associated steatohepatitis. mSystems. 2026. doi:10.1128/msystems.00292-26
BibTeX
@article{Guo2026,
author = {Guo, Jing and Xiang, Zhong-Wen and Hu, Fang-Fang and Zhang, Song-Xia and Han, Wen-Jing and Ding, Xin and Wang, Xin and Ye, Meng-Ling and Chen, Jun-Hong and Rao, Tai and Wu, Lie-Lin and Lian, Guang-Hui and Zhang, Wei and Huang, Yun and Chen, Yao},
title = {Turicibacter sanguinis is a candidate gut microbial pathobiont that promotes metabolic dysfunction-associated steatohepatitis},
journal = {mSystems},
year = {2026},
doi = {10.1128/msystems.00292-26}
}
EUVIMED